SUVEN

Suven Life Sciences Limited

Suven Life Sciences Limited (SUVEN) financial statements and selected valuation metrics through 30 June 2026.

Healthcare›Healthcare›Healthcare Services›Healthcare Research, Analytics & Technology

suven.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹303.55
Market cap
8,577 Cr
Stock P/E
Loss (TTM EPS ₹-13.79)
P/B
13.54
ROE (FY26)
-46.7%
ROCE (FY26)
-46.7%
Operating margin (FY26)
-4077.7%
OCF / EBITDA (3Y)
-36.4%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Suven Life Sciences is a clinical-stage biopharmaceutical company that discovers and develops new chemical entities for central nervous system (CNS) disorders such as agitation in Alzheimer's dementia and major depression.

Company snapshot

3rdBy market cap

Ranked among 5 companies in Healthcare Research, Analytics & Technology.

Segment mix

Reportable segments as of 2019-09-30 (Consolidated). Revenue share = segment revenue ÷ total revenue.

Largest segment: 97.9% of revenue

SegmentRevenue shareRevenuePBTAssets
Manufacturing (CRAMS)
97.9%
463 Cr231 Cr—
Research & Development—0 Cr-66 Cr—
Services (DDDSS)
2.1%
10 Cr2 Cr—

What we see

Concerns
  • ✗Net margin is negative — the company is spending more than it earns right now.
3 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales3 Cr2 Cr2 Cr1 Cr3 Cr2 Cr1 Cr2 Cr0.92 Cr3 Cr2 Cr4 Cr
Operating expenses (approx.)27 Cr49 Cr33 Cr32 Cr55 Cr41 Cr45 Cr53 Cr81 Cr106 Cr52 Cr136 Cr
EBITDA-24 Cr-46 Cr-30 Cr-31 Cr-52 Cr-39 Cr-44 Cr-51 Cr-80 Cr-103 Cr-51 Cr-133 Cr
OPM %-768.4%-1884.8%-1269.8%-3035.6%-2029.2%-2435.3%-2987.1%-2718.6%-8678.3%-3679.7%-3330.9%-3715.9%
Other income5 Cr6 Cr4 Cr4 Cr4 Cr2 Cr1 Cr0.60 Cr4 Cr3 Cr7 Cr8 Cr
Interest0.04 Cr0.04 Cr0.03 Cr0.02 Cr0.02 Cr0.0079 Cr0 Cr0 Cr0 Cr0 Cr0.16 Cr0.48 Cr
Depreciation2 Cr2 Cr2 Cr1 Cr1 Cr2 Cr1 Cr1 Cr1 Cr1 Cr2 Cr2 Cr
Profit before tax-13 Cr-42 Cr-28 Cr-28 Cr-50 Cr-39 Cr-44 Cr-52 Cr-77 Cr-102 Cr-46 Cr-128 Cr
Tax %0.0%0.0%3.6%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net profit-13 Cr-42 Cr-27 Cr-28 Cr-50 Cr-39 Cr-44 Cr-52 Cr-77 Cr-102 Cr-46 Cr-128 Cr
EPS (₹)₹-0.58₹-1.92₹-1.22₹-1.29₹-2.27₹-1.79₹-2.02₹-2.36₹-3.48₹-4.55₹-2.02₹-4.84

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales544 Cr625 Cr664 Cr14 Cr13 Cr12 Cr14 Cr12 Cr7 Cr7 CrSign in free for the trailing twelve months
Operating expenses (approx.)415 Cr427 Cr503 Cr130 Cr94 Cr134 Cr139 Cr140 Cr172 Cr292 CrSign in free for the trailing twelve months
EBITDA129 Cr198 Cr160 Cr-116 Cr-80 Cr-122 Cr-126 Cr-128 Cr-166 Cr-285 CrSign in free for the trailing twelve months
OPM %23.7%31.7%24.2%-802.8%-594.0%-1033.3%-929.8%-1094.7%-2490.7%-3998.8%Sign in free for the trailing twelve months
Other income21 Cr23 Cr24 Cr14 Cr8 Cr5 Cr8 Cr21 Cr11 Cr14 CrSign in free for the trailing twelve months
Interest6 Cr5 Cr4 Cr0.55 Cr0.82 Cr0.53 Cr0.29 Cr0.16 Cr0.05 Cr0.16 CrSign in free for the trailing twelve months
Depreciation21 Cr21 Cr22 Cr4 Cr4 Cr4 Cr7 Cr7 Cr6 Cr6 CrSign in free for the trailing twelve months
Profit before tax123 Cr196 Cr159 Cr-106 Cr-77 Cr-122 Cr-118 Cr-106 Cr-161 Cr-276 CrSign in free for the trailing twelve months
Tax %29.2%36.7%45.2%11.5%6.9%0.0%0.0%0.9%0.0%0.0%Sign in free for the trailing twelve months
Net profit87 Cr124 Cr87 Cr-94 Cr-72 Cr-122 Cr-118 Cr-105 Cr-161 Cr-276 CrSign in free for the trailing twelve months
EPS (₹)₹6.84₹9.70₹6.83₹-2.01₹-5.67₹-9.57₹-6.63₹-4.82₹-7.37₹-12.13Sign in free for the trailing twelve months
Dividend payout %——————————Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital13 Cr13 Cr13 Cr13 Cr13 Cr15 Cr22 Cr22 Cr22 Cr26 Cr
Reserves654 Cr755 Cr818 Cr131 Cr95 Cr82 Cr354 Cr248 Cr88 Cr565 Cr
Borrowings56 Cr26 Cr37 Cr1 Cr0.39 Cr0.48 Cr————
Other liabilities92 Cr120 Cr171 Cr37 Cr20 Cr11 Cr14 Cr15 Cr25 Cr33 Cr
Total liabilities816 Cr914 Cr1,039 Cr182 Cr128 Cr108 Cr389 Cr285 Cr135 Cr624 Cr
Fixed assets (net)304 Cr305 Cr291 Cr21 Cr18 Cr35 Cr36 Cr27 Cr59 Cr56 Cr
CWIP10 Cr25 Cr111 Cr—5 Cr4 Cr0 Cr0 Cr0.0097 Cr4 Cr
Investments301 Cr279 Cr230 Cr0.05 Cr0.09 Cr45 Cr46 Cr76 Cr22 Cr0 Cr
Loans & advances——0.11 Cr42 Cr41 Cr0 Cr0 Cr0 Cr0 Cr0 Cr
Inventories93 Cr139 Cr157 Cr0 Cr0.14 Cr0.02 Cr0 Cr0.71 Cr0.24 Cr0.10 Cr
Trade receivables46 Cr62 Cr150 Cr2 Cr2 Cr1 Cr0.81 Cr1 Cr1 Cr2 Cr
Cash & bank9 Cr20 Cr11 Cr15 Cr9 Cr5 Cr37 Cr15 Cr15 Cr8 Cr
Other assets54 Cr84 Cr89 Cr102 Cr53 Cr18 Cr269 Cr165 Cr37 Cr555 Cr
Total assets816 Cr914 Cr1,039 Cr182 Cr128 Cr108 Cr389 Cr285 Cr135 Cr624 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity109 Cr70 Cr36 Cr-194 Cr-133 Cr-128 Cr-208 Cr-83 Cr-154 Cr-302 Cr
Cash from investing-311 Cr-0.61 Cr-28 Cr206 Cr93 Cr-22 Cr-156 Cr62 Cr155 Cr-462 Cr
Cash from financing-30 Cr-58 Cr-23 Cr3 Cr35 Cr146 Cr396 Cr-1 Cr-0.76 Cr757 Cr
Net cash flow-232 Cr12 Cr-15 Cr14 Cr-5 Cr-4 Cr32 Cr-22 Cr0.09 Cr-7 Cr
Free cash flow (OCF − Capex)79 Cr28 Cr-62 Cr-196 Cr-139 Cr-147 Cr-211 Cr-83 Cr-191 Cr-307 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %17.8%25.2%18.7%-73.3%-70.7%-125.7%-31.4%-39.2%-146.1%-46.7%
ROE %13.1%16.1%10.5%-65.7%-66.8%-126.9%-31.5%-38.9%-146.1%-46.7%
Debtor days31368257484022407377
Inventory days218290280041022135
Days payable8911810814681614565286246
Cash conversion cycle159208254-89-29-20-23-2-200-164
OCF / EBITDA %84.6%35.3%22.2%———————
OCF / EBITDA % (3 years)——44.0%-36.4%——————
Debt / equity0.080.030.040.00760.00360.0050————
Current ratio4.154.824.182.496.458.0122.6118.993.2117.69
Net debt / EBITDA0.37—0.16———————
Suven Life Sciences Limited (SUVEN) Financials | BullKarma